Comparison of conditioning regimen toxicities among autologous stem cell transplantation eligible multiple myeloma patients: High-dose melphalan versus high-dose melphalan and bortezomib

Aypar, Eda; Izzettin, Fikret; Aki, Sahika; SANCAR, MESUT; YEGİN, ZEYNEP; Turkoz-Sucak, Gulsan

doi:10.1177/1078155217697486

Comparison of conditioning regimen toxicities among autologous stem cell transplantation eligible multiple myeloma patients: High-dose melphalan versus high-dose melphalan and bortezomib

Atıf İçin Kopyala

Aypar E., Izzettin F. V., Aki S. Z., SANCAR M., YEGİN Z. A., Turkoz-Sucak G.

JOURNAL OF ONCOLOGY PHARMACY PRACTICE, cilt.24, sa.4, ss.281-289, 2018 (SCI-Expanded)

Yayın Türü: Makale / Tam Makale
Cilt numarası: 24 Sayı: 4
Basım Tarihi: 2018
Doi Numarası: 10.1177/1078155217697486
Dergi Adı: JOURNAL OF ONCOLOGY PHARMACY PRACTICE
Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
Sayfa Sayıları: ss.281-289
Gazi Üniversitesi Adresli: Evet

Özet

Background Autologous hematopoietic stem cell transplantation (AHSCT) remains the standard of care for younger patients with multiple myeloma (MM). Currently, high-dose melphalan (HDM) is recommended as conditioning regimen before AHSCT. Preclinical data suggest that combining bortezomib and melphalan has synergistic effect against multiple myeloma cells. Bortezomib and HDM (Bor-HDM) combination as conditioning regimen has been investigated by many other investigators.